Research Analysts Issue Forecasts for THTX FY2027 Earnings

Theratechnologies Inc. (NASDAQ:THTX) – Analysts at Leede Financial issued their FY2027 earnings estimates for Theratechnologies in a report issued on Wednesday, February 26th. Leede Financial analyst D. Loe forecasts that the company will post earnings per share of $0.23 for the year. The consensus estimate for Theratechnologies’ current full-year earnings is $0.01 per share. Leede Financial also issued estimates for Theratechnologies’ FY2027 earnings at $0.23 EPS.

Separately, Research Capitl raised Theratechnologies to a “strong-buy” rating in a report on Friday, February 14th.

Theratechnologies Stock Up 1.9 %

NASDAQ THTX opened at $1.65 on Friday. The company has a market cap of $75.87 million, a PE ratio of -16.50 and a beta of 1.26. Theratechnologies has a 52 week low of $1.08 and a 52 week high of $2.18. The firm’s 50-day simple moving average is $1.74 and its two-hundred day simple moving average is $1.45.

Institutional Trading of Theratechnologies

Several institutional investors and hedge funds have recently modified their holdings of the business. Harbour Investments Inc. raised its holdings in shares of Theratechnologies by 20.0% in the 4th quarter. Harbour Investments Inc. now owns 87,772 shares of the company’s stock valued at $159,000 after acquiring an additional 14,655 shares in the last quarter. Raymond James Financial Inc. purchased a new position in shares of Theratechnologies in the 4th quarter worth about $27,000. Bank of America Corp DE boosted its holdings in shares of Theratechnologies by 1,416.7% in the 4th quarter. Bank of America Corp DE now owns 16,487 shares of the company’s stock worth $30,000 after purchasing an additional 15,400 shares in the last quarter. JPMorgan Chase & Co. purchased a new position in shares of Theratechnologies in the 4th quarter worth about $33,000. Finally, Wealthspire Advisors LLC boosted its holdings in shares of Theratechnologies by 39.0% in the 4th quarter. Wealthspire Advisors LLC now owns 71,250 shares of the company’s stock worth $129,000 after purchasing an additional 20,000 shares in the last quarter.

Theratechnologies Company Profile

Theratechnologies Inc, a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.